Last updated on August 2018

Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Lower Risk MDS


Brief description of study

The objective of this study to evaluate the efficacy and safety of FG-4592 for the treatment of anemia in Chinese subjects with lower risk MDS.

Detailed Study Description

This is a Phase 2/3 trial with sequential Phase 2 and Phase 3 components. In each, there is an up to 4 weeks screen period followed by a treatment period of 26 weeks and a 4 week follow up period.

Clinical Study Identifier: NCT03303066

Find a site near you

Start Over